Anxiety, Depression
Conditions
Brief summary
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial. The financial burden of treatment failures in direct treatment costs, disability, decreased productivity, and missed work may in part derive from a mismatch between optimal, and actual, medications prescribed. The present one year retrospective study seeks to evaluate the indirect and direct healthcare costs for 96 patients with a DSM-IV-TR depressive or anxiety disorder, in relation to an interpretive reporting system designed to predict antidepressant responses based on DNA variations in cytochrome P450 genes (CYP2D6, CYP2C19, CYP1A2), the serotonin transporter gene (SLC6A4), and the serotonin 2A receptor (5HTR2A) genes.
Interventions
None listed
Sponsors
Assurex Health Inc.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Major Depressive Disorder * Dysthymic Disorder * Depressive Disorder NOS * Obsessive Compulsive Disorder (OCD) * Generalized Anxiety Disorder * Panic Disorder * Anxiety Disorder NOS * Post-Traumatic Stress Disorder (PTSD) * Social Phobia
Exclusion criteria
* Bipolar Disorder * Schizophrenia * Schizoaffective Disorder * Previous pharmacogenomic testing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Outpatient Visits | During the one year study window (April 1, 2010 to April 1, 2011) | Number of outpatient healthcare visits during study window |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Medical Absence Days | During the one year study window (April 1, 2010 to April 1, 2011) | Number of medical absence days during study window |
| Number of Disability Claims | During the one year study window (April 1, 2010 to April 1, 2011) | Number of disabiity claims during study window |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Depression and Anxiety Subjects with a primary diagnosis of depression or anxiety disorder. | 104 |
| Total | 104 |
Baseline characteristics
| Characteristic | Depression and Anxiety |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 7 Participants |
| Age, Categorical Between 18 and 65 years | 97 Participants |
| Age, Continuous | 50.9 years STANDARD_DEVIATION 11.9 |
| Region of Enrollment United States | 104 participants |
| Sex: Female, Male Female | 68 Participants |
| Sex: Female, Male Male | 36 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 104 |
| serious Total, serious adverse events | 0 / 104 |
Outcome results
Primary
Number of Outpatient Visits
Number of outpatient healthcare visits during study window
Time frame: During the one year study window (April 1, 2010 to April 1, 2011)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Depression and Anxiety | Number of Outpatient Visits | 13 units on a scale | Standard Deviation 9.4 |
Secondary
Number of Disability Claims
Number of disabiity claims during study window
Time frame: During the one year study window (April 1, 2010 to April 1, 2011)
Secondary
Number of Medical Absence Days
Number of medical absence days during study window
Time frame: During the one year study window (April 1, 2010 to April 1, 2011)